Sagimet Biosciences (SGMT) Earnings Date & Reports

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SGMT is expected to report earnings to rise 42.00% to -70 cents per share on May 14

Sagimet Biosciences SGMT Stock Earnings Reports

Q1'25

Est.

$-0.71

Q4'24

Missed

by $0.01

Q3'24

Beat

by $0.10

Q2'24

Beat

by $0.25

Q1'24

Beat

by $0.24

The last earnings report on March 12 showed earnings per share of -50 cents, missing the estimate of -49 cents. With 1.56M shares outstanding, the current market capitalization sits at 83.06M.

View a ticker or compare two or three

Compare

SGMT